Literature DB >> 14500754

Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor.

Amy M Avila1, Martha I Dávila-García, Veronica S Ascarrunz, YingxIan Xiao, Kenneth J Kellar.   

Abstract

Neuronal nicotinic receptors in PC12 cells were measured by binding with [3H]epibatidine and in functional studies with agonist-stimulated 86Rb+ efflux and [3H]norepinephrine release assays. Two subtypes of receptors labeled by [3H]epibatidine were found: one that was increased about 4-fold in cells grown for 2 to 4 days in the presence of nicotine and one that was increased 5-fold in cells grown for 2 to 4 days in the presence of nerve growth factor (NGF). The actions of the two treatments were superadditive, resulting in approximately a 13-fold increase in binding sites in cells grown in the combination of the two treatments. The pharmacology of the binding sites in the nicotine- and NGF-treated cells was compared with the pharmacology of defined alpha3beta2 and alpha3beta4 nicotinic acetylcholine receptor (nAChR) subtypes heterologously expressed in human embryonic kidney 293 cells. Nicotine treatment predominantly increased a receptor with characteristics of an alpha3beta2 subtype, whereas the NGF treatment exclusively increased a receptor with characteristics of an alpha3beta4 subtype. Nicotinic receptor-mediated function measured with the 86Rb+ efflux assay was evident only in the NGF-treated cells, and it had a pharmacological profile that was, again, nearly identical to that of the heterologously expressed alpha3beta4 receptor subtype. Receptor function measured with the [3H]norepinephrine release assay was measurable in both nicotine-treated and NGF-treated cells; however, cytisine-stimulated [3H]norepinephrine release indicated that nicotine treatment increased an nAChR containing beta2 subunits, whereas NGF increased a receptor containing beta4 subunits. NGF treatment increased mRNA only for beta4 subunits in these cells, whereas nicotine treatment did not affect mRNA for any of the subunits measured. After withdrawal of the treatments, the receptors increased by nicotine were much less stable than those increased by NGF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500754     DOI: 10.1124/mol.64.4.974

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

2.  The Effects of Nerve Growth Factor on Nicotinic Synaptic Transmission in Mouse Airway Parasympathetic Neurons.

Authors:  Letitia A Weigand; Kevin Kwong; Allen C Myers
Journal:  Am J Respir Cell Mol Biol       Date:  2015-10       Impact factor: 6.914

3.  Dp71, utrophin and beta-dystroglycan expression and distribution in PC12/L6 cell cocultures.

Authors:  Ramses Ilarraza-Lomeli; Bulmaro Cisneros-Vega; Maria de Lourdes Cervantes-Gomez; Dominique Mornet; Cecilia Montañez
Journal:  Neuroreport       Date:  2007-10-29       Impact factor: 1.837

4.  Endogenously expressed muscarinic receptors in HEK293 cells augment up-regulation of stably expressed α4β2 nicotinic receptors.

Authors:  Gregory P Hussmann; Robert P Yasuda; Yingxian Xiao; Barry B Wolfe; Kenneth J Kellar
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

5.  Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation.

Authors:  Sarah E McCallum; Allan C Collins; Richard Paylor; Michael J Marks
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

6.  Amelioration strategies fail to prevent tobacco smoke effects on neurodifferentiation: Nicotinic receptor blockade, antioxidants, methyl donors.

Authors:  Theodore A Slotkin; Samantha Skavicus; Jennifer Card; Edward D Levin; Frederic J Seidler
Journal:  Toxicology       Date:  2015-04-17       Impact factor: 4.221

7.  MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition.

Authors:  Jerry J Buccafusco; James C Powers; Maria A Hernandez; Mark A Prendergast; Alvin V Terry; Ramamohana R Jonnala
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

8.  Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.

Authors:  G Patrick Hussmann; Jill R Turner; Ermelinda Lomazzo; Rashmi Venkatesh; Vanessa Cousins; Yingxian Xiao; Robert P Yasuda; Barry B Wolfe; David C Perry; Amir H Rezvani; Edward D Levin; Julie A Blendy; Kenneth J Kellar
Journal:  J Pharmacol Exp Ther       Date:  2012-08-16       Impact factor: 4.030

9.  Alpha 7 nicotinic acetylcholine receptor expression and activity during neuronal differentiation of PC12 pheochromocytoma cells.

Authors:  Arthur A Nery; Rodrigo R Resende; Antonio H Martins; Cleber A Trujillo; Vesna A Eterovic; Henning Ulrich
Journal:  J Mol Neurosci       Date:  2010-05-12       Impact factor: 3.444

10.  Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro.

Authors:  Theodore A Slotkin; Frederic J Seidler; Fabio Fumagalli
Journal:  Brain Res Bull       Date:  2008-02-01       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.